Urology Times staff

Lead author Ian Davis, MBBS, PhD, discusses the results of the ENZAMET study update he shared during the 2022 ASCO Annual Meeting.

"We need to try to do as much as we can to limit sepsis, and basing it on the patient's preoperative risk factors can be very helpful," says Naeem Bhojani, MD, FRCSC.

The target of the the PET-imaging agent 64Cu SAR-Bombesin is the Gastrin Releasing Peptide receptor (GRPr), which is found on prostate tumors as well as several other tumors

“I think immunotherapy in the neoadjuvant and also in the BCG-unresponsive setting are here to stay,” says Roger Li, MD.

In this interview, Eila C. Skinner, MD, discusses neobladder reconstruction in patients undergoing radical cystectomy.

Rao is an investigator on the ongoing phase 3 CASPAR trial exploring the AR pathway inhibitor enzalutamide combined with the PARP inhibitor rucaparib in patients with mCRPC.

"It's not perfect; you have to sort of retrain it, and there are some downsides to it. But it's the closest that we can get to, essentially, an artificial bladder," says Eila C. Skinner, MD.

“Less than half of the videos actually featured a medical provider, so a majority of videos are being produced by non-medical providers, commercial media, or individual YouTubers with no medical experience,” says Connie Huang, MD.

“We found in ARCHES that in the men who developed radiographic progression while on ADT-enzalutamide [Xtandi], two thirds of these patients, when they had radiographic progression, did not meet PSA progression criteria, and one third didn't have any rise at all in their PSA,” says Andrew J. Armstrong, MD, MSc.

Based on the efficacy of the LITESPARK-001 study, the phase 3 LITESPARK-005 study of belzutifan has already been launched, says Eric Jonasch, MD.

“This analysis has a median follow-up of 41 months,” says Jonasch.

The new findings, “further support the use of adjuvant pembrolizumab after nephrectomy as a standard of care in patients with localized renal cell carcinoma at increased risk for recurrence,” says Toni K. Choueiri, MD.

Janet Kukreja, MD, discusses 5 studies in bladder cancer being presented at the 2022 ASCO Annual Meeting.

Michael S. Cookson, MD, MMHC, discusses 5 studies in prostate cancer being presented at the 2022 ASCO Annual Meeting.

"We're all very aware of the impact that prostate-specific antigen [PSA] has had on screening for prostate cancer. What's underappreciated is how the biopsy technique pivoted at about the same time," says Adam S. Kibel, MD.

In this video, Adam S. Kibel, MD, discusses the development of transrectal ultrasound-guided prostate biopsy and how prostate biopsy has continued to evolve over the years.

“What would be wonderful is to have a strong, smart triaging system,” says Shirley Lee, CRNP-FNP, MPH.

“I think the one thing that we're hopeful for is that people will start to look at vitamin D as a potential chemoprevention agent,” says Adam B. Murphy, MD, MBA, MSCI.

“A lot of people that are fatigued [and] a lot of people that have back pain assume it's something else, and we have the same masculinity concerns or embarrassment concerns about reporting gynecomastia. So, all these things feed into a potential in delaying diagnosis,” says Bradley C. Leibovich, MD, FACS.

“Our main finding was that participants who reported food insecurity in the past year were 65%, more likely to experience urge incontinence compared to those who were food secure,” says Chihiro Okada.

“We know that erectile dysfunction is really an important issue that can be a harbinger for other underlying cardiovascular or neurological health issues,” says Michael Lutz, MD.

"The true innovation is finding better ways to do focal therapy that decreases the side effects for the patients and still treats the lesion effectively," says Jennifer A. Linehan, MD.

"In trying to localize and focalize the treatment on just the lesion of prostate cancer, HIFU was incredibly powerful in the sense that it really allowed you to do that with great precision," said Jennifer Linehan, MD.

"We wanted to implement an opioid minimization pathway that was easy to follow and successful,” says Aaron Laviana, MD.

The study evaluated holmium laser enucleation of the prostate, open simple prostatectomy, and robotic simple prostatectomy.

“I think we often encourage our patients to share concerns about depression, anxiety, and other mental health conditions, yet are less likely ourselves to seek help due to this issue of stigma,” says Raj S. Pruthi, MD, MHA, FACS.

Support for the application comes in large part from the phase 2/3 QUILT-3.032 trial.

The study showed that the PSMA-targeting fluorophore IS-002 enabled enhanced intraoperative tumor detection during robotic prostatectomy.

In the PADRES trial, neoadjuvant axitinib facilitated partial nephrectomy in patients with clear cell renal cell carcinoma and complex masses with an imperative indication for nephron-sparing surgery but no viable pathway to receive the procedure.

“We found that men with an elevated FSH but a normal semen test were more likely to have a decline in their sperm concentration and their total motile sperm count over time…when compared to men also starting with the normal semen test but with a normal FSH,” says Joshua Halpern, MD.